Imigran-T

Sumatriptan succinate, the active ingredient in Imigran‑T, is a Triptan presented as an oral dosage form for oral use. It is indicated for the acute treatment of migraine attacks in adults and provides rapid relief of headache and associated symptoms.

GNH USA supplies Imigran‑T as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran‑T belongs to the triptan class and is used to treat migraine-related conditions.

- Migraine without aura: rapid relief of headache, nausea, and photophobia during an acute attack. - Migraine with aura: reduction of headache severity after the aura phase when taken early. - Acute episodic migraine: termination of an attack when administered at the first sign of pain.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Nausea or abdominal upset - Dizziness or light‑headedness - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain - Serotonin syndrome when combined with serotonergic agents - Severe allergic reaction (anaphylaxis) - Sudden increase in blood pressure - Cardiac arrhythmias

Imigran‑T should be used with caution in patients with certain medical conditions and in specific situations. - Cardiovascular assessment: avoid in patients with known coronary artery disease, uncontrolled hypertension, or history of stroke. - Serotonergic agents: do not combine with other serotonergic drugs due to risk of serotonin syndrome. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Age: exercise caution in elderly patients because of increased cardiovascular susceptibility. - Drug interactions: review all concomitant medications before initiating therapy. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Sumatriptan may interact with several drug classes that affect serotonergic pathways or cardiovascular function.

Major Interactions (Avoid): - SSRIs/SNRIs: increased risk of serotonin syndrome. - Ergotamine derivatives: additive vasospastic effects. - MAO inhibitors: heightened serotonergic activity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive response. - CYP3A4 inhibitors: can raise sumatriptan plasma concentrations.